Integrating Immune Therapies for the Treatment of Multiple Myeloma
Source : https://jnccn.org/view/journals/jnccn/21/12/article-p1303.xml
Patients with relapsed or refractory multiple myeloma (RRMM) that is refractory to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody (triple-class refractory MM) have poor outcomes. Recently,...
As of September 2023, 2 BCMA-targeting CAR T-cell products, 2 BCMA-targeting BsAbs, and 1 GPRC5D-targeting BsAb, are FDA-approved for standard-of-care use in patients with RRMM who received ≥4 prior lines of therapy, including prior treatment with a proteasome inhibitor, an IMiD, and an anti-CD38 antibody.
Severe SARS-CoV-2 and Subsequent Fungal Infections After CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: a Challenging and Happy Ending Fight
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10698652/
Chimeric antigen receptor (CAR) T-cells have unveiled a promising therapeutic horizon for relapsed/refractory multiple myeloma (R/R MM).
As shown by this case, CAR T-cell recipients can be affected by a complex immune impairment exposing them to severe COVID-19 infections.
Treatment Preferences of Patients With Relapsed or Refractory Multiple Myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: Results From a Discrete Choice Experiment
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702501/
Newer treatment options for relapsed/refractory multiple myeloma (RRMM) with efficacy and safety profiles that differ from traditional therapies have facilitated personalized management strategies to optimize patient outcomes.
This robust, quantitative patient preference study found that treatment preferences were strongly driven by maximizing treatment efficacy (ORR and OS) compared with other treatment characteristics related to therapeutic administration methods and risk of specified side effects.
Survival in Multiple Myeloma and SARS-COV-2 Infection Through the COVID-19 Pandemic: Results From the EPICOVIDEHA Registry
Source : https://pubmed.ncbi.nlm.nih.gov/38050405/
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological...
The majority of patients (52%) with MM showed a critical/severe infection requiring hospitalization (64%). Overall, these data suggest that patients with MM remain vulnerable to SARS-CoV-2 infection even in the vaccination era, but also that these patients have progressively improved their OS throughout the different viral phases of pandemic.
Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: a Case Report
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673342/
The burden of melanoma is increasing globally. Despite the use of immunotherapy and targeted therapy, the prognosis of metastatic melanoma remains relatively poor. The integration of comprehensive molecular profiling can...
The presented case highlights the need to test broadly in clinical practice considering that they can impact prognosis when standard of care fails.